E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore to Announce Fourth Quarter and Year Ended December 31, 2022 Financial Results on Wednesday, March 8
March 01, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial...
Featured Image for SportGait
SPORTGAIT'S BKG (trademarked) PATENTED GAIT TECHNOLOGY PREDICTIVE CAPABILITIES VETTED AND PUBLISHED
February 23, 2023 13:16 ET | SportGait (sportgait.com)
WILMINGTON, N.C., Feb. 23, 2023 (GLOBE NEWSWIRE) -- SportGait, the brain wellness and medical technology company, proudly announced today the publication of an article in the Journal of Concussion...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore, Inc. Announces Exclusive Distribution Agreement with Byond Healthcare Pty Ltd, South Africa
February 21, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Feb. 21, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced an agreement with...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Expands Intellectual Patent Portfolio for nVNS Technology
February 16, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Feb. 16, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the United States Patent and...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Completes Sale of New Jersey Tax Benefits
February 15, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Feb. 15, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has completed the sale of...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces Reverse Stock Split
February 14, 2023 10:30 ET | electroCore, Inc.
ROCKAWAY, N.J., Feb. 14, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced a planned reverse...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces Expected Record 4Q 2022 Revenue of $2.5M; Provides Business Update
January 17, 2023 08:00 ET | electroCore, Inc.
Record revenue of approximately $2.5 million for the three months ended December 31, 2022 and $8.5 million for full-year 2022Revenue growth of approximately 57% over full-year 2021Launched two new...
New Logo July 12, 2022.png
Odyssey Health, Inc. To Develop Intranasal Field- Deliverable Nerve Agent Antidote
January 12, 2023 08:30 ET | Odyssey Health, Inc
Las Vegas Nevada, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore, Inc. Launches New Wellness Product Offering for Stress, Anxiety and Sleep, Truvaga™
December 20, 2022 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Dec. 20, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic company, today announced the launch of a new wellness product offering called...
New Logo July 12, 2022.png
Odyssey Health, Inc. Provides a Year End Update on Company and Corporate Outlook for 2023
December 19, 2022 08:30 ET | Odyssey Health, Inc
Las Vegas, Nevada, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing life-enhancing medical products, today...